Pharmaceuticals

Founded by Emma Heming Willis, Make Time Wellness unveils three new products, tapping into a booming market with science-backed solutions for women's brain health.

With one trial halted and another beginning, the company focuses its cash and hopes on BBI-940, a novel drug targeting a fundamental driver of cancer.

UK's Abselion opens a US base in Cambridge, MA, aiming to disrupt biologics R&D with its rapid Amperia protein quantification system.

IDEAYA Biosciences begins a key trial for its targeted therapy IDE892, aiming to conquer hard-to-treat tumors and pivoting to focus on its proprietary assets.

With its runway extended by insiders, the biotech firm bets on its promising glioblastoma drug and an unconventional strategy of crypto and acquisitions.

Early access programs for a rare blindness therapy in France, Israel, and the US offer hope to patients and provide a crucial financial lifeline for the company.

A new trial in China tests a dual-action antibody for esophageal cancer, a top killer. The therapy aims to unleash a two-pronged immune attack on tumors.

Amid rising avian flu concerns, Canada secures millions of next-gen cell-based vaccines, upgrading its pandemic response arsenal for faster protection.

Eli Lilly and the WHO Foundation have launched a new collaboration to strengthen health systems and combat the escalating obesity crisis in underserved regions.

French pharma giant Servier acquires Day One Biopharmaceuticals, gaining a breakthrough pediatric cancer drug and signaling a major push into rare oncology.

Atlas Health's new AI agent, Ava, aims to tackle the healthcare affordability crisis by automating access to financial assistance programs.

A landmark court decision certifies a massive class action against Johnson & Johnson, alleging its Baby Powder caused cancer and the company misled consumers.

A new drug for Raynaud's phenomenon in scleroderma patients significantly boosts attack-free days, offering hope despite missing its primary trial goal.

Artelo Biosciences executes a reverse stock split to fight delisting, but will the financial maneuver be enough to fund its promising drug pipeline?

Allarity Therapeutics lands a crucial $20M debt deal to push its unique ovarian cancer drug, stenoparib, through late-stage trials and extend its runway to 2028.

With $336M in the bank and three autoimmune drugs advancing, Jade Biosciences lays out a fast-paced timeline for key clinical milestones in 2026 and 2027.

After its public debut, BBOT unveils exciting early data from three unique cancer drugs, including a first in pancreatic cancer, backed by a strong cash runway.

NextCure accelerates its high-stakes ovarian cancer drug trial, but with cash dwindling, can it reach the finish line before time runs out?

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.

Scientists find herpes melts the inside of our cells to replicate faster, a discovery that could revolutionize treatments for a host of viral diseases.